Bayer Loses Oversight Of Yaz DTC Ads Under Agreement With States Attorneys General
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has oversight over DTC advertising for Bayer’s Yaz contraceptive after the company violated an earlier agreement with state attorneys general.
You may also be interested in...
DTC Held Hostage? FDA Pre-Review of TV Ads May Delay Rx Campaigns
FDA is proposing changes to its regulation of television advertising for prescription drugs with a mandatory pre-review of ads for certain products. The agency says it has the resources to complete all reviews on time. But stakeholders worry that the draft requirements would delay campaigns and make DTC advertising more expensive. It’s not like there’s a good alternative: jumping the gun on DTC carries its own set of risks.
Bayer Tries Google Format To Keep Yaz Name In Sponsored Link And Meet Risk Requirements
The sponsored Google search result for Yaz gives no indication and links user to "full safety and prescribing information, including a boxed warning."
Bayer Tries Google Format To Keep Yaz Name In Sponsored Link And Meet Risk Requirements
The sponsored Google search result for Yaz gives no indication and links user to "full safety and prescribing information, including a boxed warning."